×
About 5,168 results

ALLMedicine™ Hyperkalemia Center

Research & Reviews  2,105 results

Does dietary potassium intake associate with hyperkalemia in patients with chronic kidn...
https://doi.org/10.1093/ndt/gfaa232
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association; Ramos CI, González-Ortiz A et. al.

Nov 28th, 2020 - Dietary potassium restriction is a strategy to control hyperkalemia in chronic kidney disease (CKD). However, hyperkalemia may result from a combination of clinical conditions. This study aimed to investigate whether dietary potassium or the intak...

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: f...
https://doi.org/10.1038/s41440-020-00569-y
Hypertension Research : Official Journal of the Japanese Society of Hypertension; Rakugi H, Yamakawa S et. al.

Nov 20th, 2020 - The nonsteroidal mineralocorticoid receptor (MR) blocker esaxerenone has demonstrated good antihypertensive activity in a variety of patients, including those with uncomplicated grade I-III hypertension, hypertension with moderate renal dysfunctio...

Assessment of a downsized potassium adsorption filter designed to transfuse neonates.
https://doi.org/10.1111/trf.16010
Transfusion REFERENCES; Ogasawara K, Ohto H et. al.

Nov 20th, 2020 - During storage, the potassium level of red blood cell (RBC) components increases, especially after irradiation. Neonates are prone to hyperkalemia, for example, non-oliguric hyperkalemia, so using potassium adsorption filters during transfusion ma...

Accuracy of Hemolyzed Potassium Levels in the Emergency Department.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673871
The Western Journal of Emergency Medicine; Wilson M, Adelman S et. al.

Nov 18th, 2020 - In the emergency department (ED), pseudohyperkalemia from hemolysis may indirectly harm patients by exposing them to increased length of stay, cost, and repeat blood draws. The need to repeat hemolyzed potassium specimens in low-risk patients has ...

Sodium zirconium cyclosilicate for hyperkalemia: a collateral acid-base benefit?
https://doi.org/10.1093/ndt/gfaa241
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association; Wesson DE

Nov 12th, 2020 - Sodium zirconium cyclosilicate for hyperkalemia: a collateral acid-base benefit?|2020|Wesson DE,|

see more →

Drugs  167 results see all →

Clinicaltrials.gov  2,549 results

Does dietary potassium intake associate with hyperkalemia in patients with chronic kidn...
https://doi.org/10.1093/ndt/gfaa232
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association; Ramos CI, González-Ortiz A et. al.

Nov 28th, 2020 - Dietary potassium restriction is a strategy to control hyperkalemia in chronic kidney disease (CKD). However, hyperkalemia may result from a combination of clinical conditions. This study aimed to investigate whether dietary potassium or the intak...

Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: f...
https://doi.org/10.1038/s41440-020-00569-y
Hypertension Research : Official Journal of the Japanese Society of Hypertension; Rakugi H, Yamakawa S et. al.

Nov 20th, 2020 - The nonsteroidal mineralocorticoid receptor (MR) blocker esaxerenone has demonstrated good antihypertensive activity in a variety of patients, including those with uncomplicated grade I-III hypertension, hypertension with moderate renal dysfunctio...

Assessment of a downsized potassium adsorption filter designed to transfuse neonates.
https://doi.org/10.1111/trf.16010
Transfusion REFERENCES; Ogasawara K, Ohto H et. al.

Nov 20th, 2020 - During storage, the potassium level of red blood cell (RBC) components increases, especially after irradiation. Neonates are prone to hyperkalemia, for example, non-oliguric hyperkalemia, so using potassium adsorption filters during transfusion ma...

Accuracy of Hemolyzed Potassium Levels in the Emergency Department.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673871
The Western Journal of Emergency Medicine; Wilson M, Adelman S et. al.

Nov 18th, 2020 - In the emergency department (ED), pseudohyperkalemia from hemolysis may indirectly harm patients by exposing them to increased length of stay, cost, and repeat blood draws. The need to repeat hemolyzed potassium specimens in low-risk patients has ...

Sodium zirconium cyclosilicate for hyperkalemia: a collateral acid-base benefit?
https://doi.org/10.1093/ndt/gfaa241
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association; Wesson DE

Nov 12th, 2020 - Sodium zirconium cyclosilicate for hyperkalemia: a collateral acid-base benefit?|2020|Wesson DE,|

see more →

News  347 results

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.staging.medscape.com/viewarticle/940012

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Dapagliflozin Halves Hyperkalemia in Some HF Patients
https://www.medscape.com/viewarticle/940012

Oct 28th, 2020 - For patients with heart failure with reduced ejection fraction (HFrEF), the addition of dapagliflozin (Farxiga) to a mineralocorticoid receptor antagonist (MRA) halved the incidence of moderate to severe hyperkalemia, a prespecified analysis of DA...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.staging.medscape.com/viewarticle/939724

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Novel Drug Slows Progression of Diabetic Kidney Disease
https://www.medscape.com/viewarticle/939724

Oct 22nd, 2020 - For patients with diabetic kidney disease, finerenone, an agent from a new class of selective, nonsteroidal mineralocorticoid receptor antagonists, led to significant reductions in combined adverse renal outcomes and in combined adverse cardiovasc...

Will Mineralocorticoid Receptor Antagonists Move Higher Up the Hypertension Treatment Pathway?
https://www.staging.medscape.com/viewarticle/936725

Sep 3rd, 2020 - Mineralocorticoid receptor antagonists (MRAs) are still finding their place in nephrology. Many of us relegate them to the bottom of our therapeutic bag for use only after we've exhausted other renin-angiotensin-aldosterone (RAAS)-modifying agents...

see more →